Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Federal Trade Commission
Dow
Citi
Express Scripts
Argus Health
Johnson and Johnson
Accenture
Merck
Queensland Health

Generated: December 11, 2017

DrugPatentWatch Database Preview

GADAVIST Drug Profile

« Back to Dashboard

When do Gadavist patents expire, and what generic alternatives are available?

Gadavist is a drug marketed by Bayer Hlthcare and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-five patent family members in sixteen countries and one supplementary protection certificate in one country.

The generic ingredient in GADAVIST is gadobutrol. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gadobutrol profile page.
Drug patent expirations by year for GADAVIST

Pharmacology for GADAVIST

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-006Dec 18, 2013RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-002Mar 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-001Mar 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-005Mar 14, 2011RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-003Mar 14, 2011RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-006Dec 18, 2013RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-001Mar 14, 2011RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-002Mar 14, 2011RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-002Mar 14, 2011RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-004Mar 14, 2011RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: GADAVIST

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-001Mar 14, 2011► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-004Mar 14, 2011► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-003Mar 14, 2011► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-005Mar 14, 2011► Subscribe► Subscribe
Bayer HlthcareGADAVISTgadobutrolSOLUTION;INTRAVENOUS201277-002Mar 14, 2011► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: GADAVIST

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,399,043 1,4,7,10-Tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them► Subscribe
6,951,639 1,4,7,10-tetraazacyclododecane butyltriols, processes for their production and pharmaceutical agents containing them► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: GADAVIST

Country Document Number Estimated Expiration
Ireland67643► Subscribe
Portugal97065► Subscribe
Australia7361091► Subscribe
Spain2074219► Subscribe
Germany10075007► Subscribe
Norway911063► Subscribe
New Zealand237461► Subscribe
Austria124405► Subscribe
HungaryT60478► Subscribe
Ireland910902► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: GADAVIST

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2001 00009Denmark► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
Merck
Harvard Business School
AstraZeneca
Express Scripts
Accenture
Cipla
Citi
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot